Alpha-O Peptides

Executive Summary

Alpha-O Peptides is a Swiss biotech company pioneering vaccine development using its proprietary self-assembling protein nanoparticle (SAPN) technology. Founded in 2016 and based in Zurich, the company leverages SAPNs to create highly immunogenic and stable vaccine candidates. The SAPN platform allows for precise engineering of antigen presentation, potentially enabling robust immune responses against challenging pathogens. While Alpha-O is still in the preclinical stage with no disclosed pipeline or funding details, its technology holds promise for both prophylactic and therapeutic vaccines. The company's focus on protein-based nanoparticles aligns with industry trends toward more effective vaccine delivery systems.

Upcoming Catalysts (preview)

• TBDPreclinical proof-of-concept data for lead vaccine candidate40% success
• Q4 2026Series A funding round or strategic partnership50% success